The anti-tumor functions of IL-2-expanded Vδ2 T cells against several tumor cancer cell lines have been investigated including human neuroblastoma, myeloma, glioblastoma, melanoma, and renal adenocarcinoma and Burkitt ́s lymphoma [29,140,141,142,146,147,148]. This evidence concerns the gene IL2 and neoplasm.